Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for a canceled ...

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...

Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA ...

The vaccine also cut the risk of recurrence or death by 44%, versus Keytruda alone. Moderna has a solid pipeline of around 45 products in development, and nearly a quarter of them are expected to ...

Moderna is working on individualized neoantigen therapy, which tailors treatment to each patient's individual cancer. The company is working with Merck and its blockbuster cancer drug Keytruda on ...

slashed the risk of recurrence or death in melanoma patients by 49% compared to Keytruda alone. Moderna has several other exciting candidates in phase 2 studies. Though the stock remains down ...

This is a way for Moderna to take a seat at the table of personalized medicine. The company’s most advanced candidate is V940-Keytruda, which entered Phase III trials in 2024. The vaccine is ...

Moderna, Inc. (NASDAQ ... an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as adjuvant treatment for ...